Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12716281 | 1.00 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL14664469 | 0.95 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL20054305 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL21408129 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL13415865 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL17343011 | 0.89 | CHRM2 (0.47) | HSD17B10SMN1; SMN2NPC1HPGDEPHX1 | |
| SCHEMBL2913442 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL2917078 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL2917080 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL2913444 | 0.86 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210765-A1 | PROCESS FOR PREPARING ALPHA-SILYLAMINE COMPOUNDS FROM ALPHA-SILYLMETHYL AZIDE COMPOUNDS | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016053017-A1 | PROCESS FOR PREPARING ALPHA-SILYLAMINE COMPOUNDS FROM ALPHA-SILYLMETHYL AZIDE COMPOUNDS | 포항공과대학교 산학협력단 | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210765-A1 | PROCESS FOR PREPARING ALPHA-SILYLAMINE COMPOUNDS FROM ALPHA-SILYLMETHYL AZIDE COMPOUNDS | ITGAL, MANBA, ITGA1 | HSD17B10 4125/4885SMN1; SMN2 253/4885NPC1 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.